Alectinib is the focus of this case report and literature review as we seek to understand side effects providers may encounter when prescribing these therapies.<h4>Case presentation</h4>We begin our report with the case of a 63-year-old Hispanic female with stage IIIA non-small cell lung cancer found to have the ALK genomic alteration. The gene discussed is ALK; the disease is non-small cell lung carcinoma.